Comparison of demographics, clinical features and relevant risk factors (independent variables) associated with osteoporosis between patients with psoriatic arthritis (PsA) with and without erosions
| All PsA patients (n=2212) | PsA patients without erosions (n=889) | PsA patients with erosions (n=567) | p Value | |
|---|---|---|---|---|
| Gender | ||||
| Male | 47.6 | 45.72 | 51.5 | 0.03 |
| Female | 52.4 | 54.28 | 48.5 | |
| Age | ||||
| Mean (SD) | 43.52 (13.83) | 44.95 (14.24) | 41.98 (14.24) | <0.01 |
| Median (IQR) | 44 (33–53) | 45 (36–54) | 41 (32–52) | |
| Health Assessment Questionnaire Score | ||||
| Mean (SD) | 0.51 (0.39) | 0.52 (0.39) | 0.49 (0.39) | 0.09 |
| Median (IQR) | 0.38 (0.14–0.75) | 0.38 (0.25–0.75) | 0.38 (0.13–0.75) | |
| Steroid | ||||
| % no use | 80.42 | 79.7 | 82.83 | 0.14 |
| % use | 19.58 | 20.3 | 17.17 | |
| Methotrexate | ||||
| % no use | 46.16 | 48.71 | 45.33 | 0.21 |
| % use | 53.84 | 51.29 | 54.67 | |
| Other disease-modifying antirheumatic drugs | ||||
| % no use | 36.39 | 39.15 | 34.89 | 0.07 |
| % use | 63.61 | 60.85 | 65.61 | |
| Biological agents | ||||
| % no use | 43.49 | 45.56 | 42.68 | 0.28 |
| % use | 56.51 | 54.44 | 57.32 | |
| Disease duration, years | 9.11 | 7.49 | 11.88 | <0.01 |
| C reactive protein, mg/dl | 2.38 | 2.13 | 2.64 | 0.34 |